Loading
A phase 1/2 trial of Sintilimab in advanced solid tumours, run by Fujian Haixi Pharmaceuticals Co., Ltd., active and no longer recruiting.
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06220318 by Fujian Haixi Pharmaceuticals Co., Ltd., with 155 participants enrolled, started 2023-07-19 and due to reach its primary completion in 2026-08-30. Interventions recorded: C019199 and Sintilimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/